Veslugen
Key Facts: Veslugen
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical research, approved in Russia as supplement
- Administration
- Oral capsules or sublingual
- Typical Dose
- 10-20 mg daily
- Frequency
- Once or twice daily
- Duration
- 10-30 day cycles
Mechanism of Action
The core hypothesis is that this very short peptide can enter cells, reach the nucleus, and bind directly to specific DNA sequences in gene promoters, acting as an epigenetic switch that tunes the activity of vascular genes. Molecular docking and cell work from the Khavinson group suggest KED may bind in the minor groove near the MKI67 (Ki-67) promoter, a proliferation marker, and may influence endothelial genes such as endothelin-1, connexins, and sirtuin-1. The story is that this helps endothelial cells maintain or restore normal function with age. These are proposed, partly computational mechanisms from a single research lineage, so read them as plausible hypotheses rather than settled biology - no classical receptor target is involved.
Research Summary
KED is named explicitly in peer-reviewed reviews of Khavinson 'ultrashort' peptides, including a 2022 International Journal of Molecular Sciences paper on neuroepigenetic mechanisms in Alzheimer's disease, where it is discussed for effects on blood-brain barrier and vascular function in cell and animal models. The reported effects - modulating gene expression, stimulating nitric oxide, normalizing endothelial markers - come mostly from in vitro studies, molecular docking, and aged-animal models, not from controlled human trials. Human data is extremely limited and consists of small Russian studies without placebo controls, and the whole evidence base sits within one research group with little independent replication. So while KED is a real, defined peptide with a more concrete mechanistic story than the tissue-extract cytomaxes, the claims about human vascular and anti-aging benefits remain preliminary. Bottom line: defined molecule, some real mechanistic literature, but no rigorous human clinical proof and research-use-only status.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
10-20 mg daily
10-20 mg daily
Once or twice daily
Vascular/circulatory bioregulator. Khavinson peptide.
Research Dosingⓘ
Scientific studies
Doses from bioregulator supplement protocols
Doses from Studies
10-20 mg daily
Duration
10-30 day cycles
Administration
Oral capsules or sublingual
Timing & Administration
Best Time to Take
Morning on empty stomach
Once or twice daily
Food Recommendation
Take on empty stomach
Why This Timing?
Peptide bioregulators typically taken fasted for optimal absorption
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Limited safety data outside Russia
- ●Not FDA approved
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9032300/
- https://www.mdpi.com/1422-0067/23/8/4259
- https://pubmed.ncbi.nlm.nih.gov/22708439/
- https://link.springer.com/article/10.1134/S2079057012040091
Research This Peptide Further
Frequently Asked Questions
What does Veslugen do?
Veslugen is the vendor spelling for Vesugen, a synthetic tripeptide with the sequence Lys-Glu-Asp (KED) from Vladimir Khavinson's Russian bioregulator program, studied as a vascular 'bioregulator.' Unlike the crude tissue-extract cytomaxes, KED is a single defined molecule (formula C15H26N4O8, around 390 Da). It has named mechanistic studies but no registered randomized human trials and no regulatory approval.
How does Veslugen work?
The core hypothesis is that this very short peptide can enter cells, reach the nucleus, and bind directly to specific DNA sequences in gene promoters, acting as an epigenetic switch that tunes the activity of vascular genes. Molecular docking and cell work from the Khavinson group suggest KED may bind in the minor groove near the MKI67 (Ki-67) promoter, a proliferation marker, and may influence endothelial genes such as endothelin-1, connexins, and sirtuin-1. The story is that this helps endothelial cells maintain or restore normal function with age. These are proposed, partly computational mechanisms from a single research lineage, so read them as plausible hypotheses rather than settled biology - no classical receptor target is involved.
Is Veslugen FDA approved?
No, Veslugen is not currently FDA approved. Current status: Preclinical research, approved in Russia as supplement
What are the side effects of Veslugen?
Reported side effects include: Generally well-tolerated, Limited safety data outside Russia, Not FDA approved. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Veslugen?
Community-reported common dose: 10-20 mg daily (Once or twice daily). Range: 10-20 mg daily. Administration: Oral capsules or sublingual. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Veslugen or used in similar applications.
Livagen
PreclinicalLivagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short "peptide bioregulators" developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism.
BioregulatorsOvagen
PreclinicalOvagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.
BioregulatorsCortagen
PreclinicalCortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) from Vladimir Khavinson's Russian peptide bioregulator program, designed as the defined-sequence stand-in for Cortexin, an older cattle brain cortex extract used in Russian neurology. It is studied mostly for nerve repair, brain function and aging, and it is not approved by the FDA or EMA. Real evidence is limited to animal experiments and Russian-institute work, with no Western randomized human trials.
BioregulatorsVesugen
PreclinicalVesugen is a synthetic tripeptide (Lys-Glu-Asp, or KED) from the Khavinson family of short peptide bioregulators, studied for vascular and neuroprotective effects. It is a research compound, not an approved drug, with no registered human clinical trials.
BioregulatorsChonluten
PreclinicalChonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.
BioregulatorsCrystagen
PreclinicalCrystagen is a synthetic tripeptide (Glu-Asp-Pro, or EDP) from the Khavinson family of short peptide bioregulators, studied as an immune and thymic regulator. It is a research compound, not an approved drug, with no registered human clinical trials. Note: many vendor pages list the wrong sequence; the correct one is Glu-Asp-Pro (EDP).
BioregulatorsWant updates on Veslugen research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.